Lung Cancer News Roundup: June 2026

Lung cancer news in June was dominated by ASCO 2026 readouts, with major movement in EGFR-mutated, ALK-positive, and small cell disease. Unlike breast cancer, lung cancer didn't see a wave of new FDA approvals this particular month—June's oncology approvals skewed toward breast, prostate, and bladder cancer—but several trials presented at ASCO are likely to drive approvals later this year. Here's what mattered.